Advanced

Prognostic significance of high hyperdiploid and tri-/tetraploid adult acute myeloid leukemia.

Lazarevic, Vladimir LU ; Rosso, Aldana LU ; Juliusson, Gunnar LU ; Antunovic, Petar; Rangert-Derolf, Åsa; Lehmann, Sören; Möllgård, Lars; Uggla, Bertil; Wennström, Lovisa and Wahlin, Anders, et al. (2015) In American Journal of Hematology 90(9). p.800-805
Abstract
Purpose To ascertain the clinical implications of high hyperdiploid (HH; 49-65 chromosomes) and tri-/tetraploid (TT; >65 chromosomes) adult acute myeloid leukemia (AML), all such cases were retrieved from the Swedish AML Registry. Results Of the 3,654 cytogenetically informative cases diagnosed between January 1997 and May 2014, 68 (1.9%) were HH (n=50)/TT (n=18). Patients with HH/TT were older than those with intermediate risk (IR) AML (median 71 years versus 67 years; P = 0.042) and less often had de novo AML (63% versus 79%; P = 0.004); no such differences were observed between HH/TT and complex karyotype (CK) AML. The overall survival (OS) was similar between patients with HH/TT and CK AML (median 0.9 years versus 0.6 years; P =... (More)
Purpose To ascertain the clinical implications of high hyperdiploid (HH; 49-65 chromosomes) and tri-/tetraploid (TT; >65 chromosomes) adult acute myeloid leukemia (AML), all such cases were retrieved from the Swedish AML Registry. Results Of the 3,654 cytogenetically informative cases diagnosed between January 1997 and May 2014, 68 (1.9%) were HH (n=50)/TT (n=18). Patients with HH/TT were older than those with intermediate risk (IR) AML (median 71 years versus 67 years; P = 0.042) and less often had de novo AML (63% versus 79%; P = 0.004); no such differences were observed between HH/TT and complex karyotype (CK) AML. The overall survival (OS) was similar between patients with HH/TT and CK AML (median 0.9 years versus 0.6 years; P = 0.082), whereas OS was significantly longer (median 1.6 years; P = 0.028) for IR AML. The OS was shorter for cases with HH than with TT (median 0.6 years versus 1.4 years; P = 0.032) and for HH/TT AMLs with adverse abnormalities (median 0.8 years versus 1.1 years; P = 0.044). Conclusions In conclusion, HH/TT AML is associated with a poor outcome, but chromosome numbers >65 and absence of adverse aberrations seem to translate into a more favorable prognosis. Thus, HH/TT AMLs are clinically heterogeneous and should not automatically be grouped as high risk. This article is protected by copyright. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
American Journal of Hematology
volume
90
issue
9
pages
800 - 805
publisher
John Wiley & Sons
external identifiers
  • pmid:26088289
  • wos:000360218000023
  • scopus:84939568787
ISSN
0361-8609
DOI
10.1002/ajh.24091
language
English
LU publication?
yes
id
a2497ac7-1fbb-4ec7-8c63-0f4652faf361 (old id 7484853)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26088289?dopt=Abstract
date added to LUP
2015-07-08 19:17:26
date last changed
2017-10-01 03:12:06
@article{a2497ac7-1fbb-4ec7-8c63-0f4652faf361,
  abstract     = {Purpose To ascertain the clinical implications of high hyperdiploid (HH; 49-65 chromosomes) and tri-/tetraploid (TT; >65 chromosomes) adult acute myeloid leukemia (AML), all such cases were retrieved from the Swedish AML Registry. Results Of the 3,654 cytogenetically informative cases diagnosed between January 1997 and May 2014, 68 (1.9%) were HH (n=50)/TT (n=18). Patients with HH/TT were older than those with intermediate risk (IR) AML (median 71 years versus 67 years; P = 0.042) and less often had de novo AML (63% versus 79%; P = 0.004); no such differences were observed between HH/TT and complex karyotype (CK) AML. The overall survival (OS) was similar between patients with HH/TT and CK AML (median 0.9 years versus 0.6 years; P = 0.082), whereas OS was significantly longer (median 1.6 years; P = 0.028) for IR AML. The OS was shorter for cases with HH than with TT (median 0.6 years versus 1.4 years; P = 0.032) and for HH/TT AMLs with adverse abnormalities (median 0.8 years versus 1.1 years; P = 0.044). Conclusions In conclusion, HH/TT AML is associated with a poor outcome, but chromosome numbers >65 and absence of adverse aberrations seem to translate into a more favorable prognosis. Thus, HH/TT AMLs are clinically heterogeneous and should not automatically be grouped as high risk. This article is protected by copyright. All rights reserved.},
  author       = {Lazarevic, Vladimir and Rosso, Aldana and Juliusson, Gunnar and Antunovic, Petar and Rangert-Derolf, Åsa and Lehmann, Sören and Möllgård, Lars and Uggla, Bertil and Wennström, Lovisa and Wahlin, Anders and Höglund, Martin and Johansson, Bertil},
  issn         = {0361-8609},
  language     = {eng},
  number       = {9},
  pages        = {800--805},
  publisher    = {John Wiley & Sons},
  series       = {American Journal of Hematology},
  title        = {Prognostic significance of high hyperdiploid and tri-/tetraploid adult acute myeloid leukemia.},
  url          = {http://dx.doi.org/10.1002/ajh.24091},
  volume       = {90},
  year         = {2015},
}